Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Istodax

Gilead Sciences

People at-risk of HIV in England could get PrEP from September

10,000 people will use Gilead’s Truvada in the upcoming trial

- PMLiVE

Not dying of ignorance – 30 years on

Behavioural changes with HIV and AIDS

Celgene building

Celgene, Agios get FDA OK for leukaemia drug Idhifa

Duo’s drug becomes first new AML therapy since Novartis' Rydapt

- PMLiVE

Aids related deaths almost halved since 2005, says UNAIDS

And 53% of people living with HIV now have access to treatment

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

Celgene building

Celgene joins PD-1 race via partnership with BeiGene

The pharma giant will pay the Chinese firm up to $980m in milestone payments

- PMLiVE

ViiV files two-drug HIV maintenance regimen

SWORD studies show treatment could maintain viral suppression

- PMLiVE

Gilead plans fightback against HIV arch-rival ViiV

Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq

- PMLiVE

Juno gives up on lead CAR-T drug after deaths

ROCKET trial for leukaemia patients ended

Celgene building

Celgene bags US priority review for cancer metabolism drug

First approval for enasidenib could be just six months away

- PMLiVE

Celgene’s president and COO to retire

Scott Smith set to succeed Dr Jacqualyn Fouse from 1 April

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links